Provincial Drug Plans for Psychedelic Therapy

The honest 2026 picture of Canadian provincial public drug plans and psychedelic-assisted therapy: coverage is largely absent. Spravato — the only Health Canada-approved psychedelic-assisted therapy product — received a CDA-AMC (Canadian Drug Agency for Medications and Costs; formerly CADTH) Do Not Reimburse recommendation in December 2020, and most provincial drug plans aligned with this recommendation. INESSS (Institut national d'excellence en santé et services sociaux, Quebec's drug-evaluation body) recommended against listing in Quebec in November 2020. Off-label generic ketamine for psychiatric use is not on any provincial drug formulary. Psilocybin and MDMA (both SAP (Health Canada's Special Access Program)-only) are not on provincial formularies — the Quebec RAMQ (Régie de l'assurance maladie du Québec) Farzin/Stephan psilocybin precedent (December 2022) is the only established Canadian provincial public-funding pathway for any psychedelic therapy. Edmonton's Misericordia/Grey Nuns AHCIP (Alberta Health Care Insurance Plan)-covered IV ketamine program is the only publicly funded outpatient ketamine pathway. This article walks through provincial drug plans across Canada and what they do and don't cover for psychedelic-assisted therapy.

Key takeaways

• Provincial drug plans largely don't cover psychedelic-assisted therapy. Spravato received CDA-AMC Do Not Reimburse (December 2020); most provinces aligned.
• Quebec RAMQ — only positive provincial precedent: Farzin/Stephan December 2022 billing precedent for SAP-approved psilocybin therapy. Modified billing codes permit further claims. Limited to psilocybin (NOT extended to ketamine, Spravato, MDMA).
• AHCIP Edmonton Misericordia/Grey Nuns IV ketamine program: only Canadian publicly funded outpatient psychiatric ketamine pathway. Ultra-resistant TRD with psychiatric referral.
• Exceptional Access programs in some provinces (Ontario EAP via SADIE portal, BC PharmaCare Special Authority) — case-by-case for non-formulary requests; rarely approved for Spravato or off-label psychedelic-assisted therapy.
• For most Canadian patients: provincial drug plans are not the realistic coverage pathway for psychedelic-assisted therapy. Private prior-auth, workers' compensation, or VAC are more accessible.

The CDA-AMC and INESSS context

In December 2020, the Canadian Drug Expert Committee (CDEC) — operating under what was then CADTH and is now CDA-AMC — issued a final recommendation Do Not Reimburse for Spravato (esketamine) for treatment-resistant depression. The committee cited:

• Uncertain demonstrated benefit relative to comparators
• Difficulty identifying patients most likely to benefit
• Cost-effectiveness concerns
• Concerns about appropriate use ahead of established alternatives

The full CDA-AMC recommendation: Spravato CDEC Final Recommendation (December 2020).

INESSS (Quebec's drug-evaluation body) recommended against listing Spravato on RAMQ in November 2020 — Quebec aligned with the broader Canadian recommendation. Source: INESSS Spravato extract notice.

Most provincial drug plans aligned with the CDA-AMC recommendation and did not list Spravato on standard formularies. This shaped the Canadian provincial-drug-plan psychedelic-assisted-therapy landscape: provincial drug plans are generally not a realistic pathway.

Province-by-province breakdown

Ontario — Ontario Drug Benefit (ODB)

• Spravato: not on standard ODB (Ontario Drug Benefit) formulary. EAP (Exceptional Access Program) requests via SADIE portal — case-by-case approval; rarely approved.
• Off-label generic ketamine: not on ODB formulary.
• Psilocybin and MDMA: not on ODB formulary.

For Ontario clinical context: Ketamine Therapy in Toronto and the GTA, Ketamine Therapy in Mississauga.

British Columbia — BC PharmaCare

• Spravato: non-benefit decision. Not on formulary. Special Authority pathway exists for non-formulary drugs but is rarely approved for Spravato.
• Off-label generic ketamine: not on formulary.
• Psilocybin and MDMA: not on formulary.

BC's CPSBC has issued an August 2025 ketamine guidance update; clinical pathway is private. For BC clinical context: Ketamine Therapy in Vancouver, Ketamine Therapy in Victoria BC, Ketamine Therapy in Kelowna.

Quebec — RAMQ

• Spravato: INESSS recommended against listing November 2020. Not on RAMQ standard formulary.
• Off-label generic ketamine: not on formulary.
• Psilocybin: established public-funding pathway via the Farzin/Stephan December 2022 precedent for SAP-approved patients. RAMQ modified billing codes for further claims. The only positive Canadian provincial precedent for any psychedelic-assisted therapy. See Quebec RAMQ Coverage for Psychedelic Therapy.
• MDMA: not extended; not on RAMQ formulary.

For Quebec context: Psilocybin Therapy in Quebec, MDMA-Assisted Therapy in Quebec, Ketamine Therapy in Montreal.

Alberta — AHCIP and Alberta Health

• Spravato: not on standard provincial formulary. Alberta Blue Cross PAT (March 2024) is a separate private insurance framework — see Alberta Blue Cross PAT Coverage.
• Off-label generic ketamine: AHCIP coverage exists for the Edmonton Misericordia/Grey Nuns IV ketamine program — Canada's only publicly funded outpatient psychiatric ketamine pathway. See Edmonton Misericordia/Grey Nuns Public Ketamine Program.
• Psilocybin and MDMA: not on Alberta provincial formulary.

For Alberta context: Ketamine Therapy in Calgary, Ketamine Therapy in Edmonton.

Saskatchewan — Saskatchewan Drug Plan

• Spravato: not on standard formulary. Exception Drug Status (EDS) pathway exists; rarely approved.
• Off-label generic ketamine: not on formulary.
• Psilocybin and MDMA: not on formulary.

For Saskatchewan context: Ketamine Therapy in Saskatoon.

Manitoba — Manitoba Pharmacare

• Spravato: not on standard formulary.
• Off-label generic ketamine: not on formulary.
• Psilocybin and MDMA: not on formulary.

For Manitoba context: Ketamine Therapy in Winnipeg.

Atlantic provinces — Pharmacare programs

• Nova Scotia Pharmacare, New Brunswick Drug Plans, PEI Pharmacare, NL Pharmacare: Spravato generally not on standard formularies. Off-label ketamine, psilocybin, and MDMA also not covered.

For Atlantic context: Ketamine Therapy in Halifax.

Exceptional Access pathways

Several provinces have Exceptional Access or Special Authority mechanisms for non-formulary drug requests:

• Ontario EAP (Exceptional Access Program) via SADIE portal
• BC PharmaCare Special Authority
• Saskatchewan Exception Drug Status
• Other provincial mechanisms

For psychedelic-assisted therapy products:

• Spravato: theoretically eligible for exceptional-access requests, but historical approval is rare given CDA-AMC Do Not Reimburse recommendation
• Off-label generic ketamine: typically not appropriate for exceptional-access (used outside approved indication)
• Psilocybin and MDMA: SAP-only; the SAP framework is the relevant access pathway, not provincial exceptional access

The realistic 2026 picture: provincial exceptional-access pathways are rarely the realistic route for psychedelic-assisted therapy despite their theoretical availability.

Why provincial drug plans don't cover psychedelic-assisted therapy more broadly

Several structural factors:

1. CDA-AMC Do Not Reimburse for Spravato (December 2020) and INESSS aligned recommendation — most provinces aligned with the federal recommendations
2. Off-label psychiatric ketamine has no Canadian approved indication, which closes standard formulary inclusion
3. Psilocybin and MDMA SAP framework is patient-specific and physician-initiated — not designed for provincial formulary inclusion
4. Cost-effectiveness uncertainty at the published evidence level
5. Public health budget priorities focus first-line and second-line treatments before novel third-line interventions

The honest framing: Canadian provincial drug plans are unlikely to substantially expand psychedelic-assisted therapy coverage in the near term absent:

• New CDA-AMC recommendations following Phase 3 trial data updates
• Health Canada Notice of Compliance for psilocybin (Compass Pathways most likely candidate) or MDMA-AT (Lykos pursuing additional Phase 3)
• Clinical-economic evidence supporting cost-effectiveness arguments for provincial formulary inclusion

What this means for Canadian patients

The realistic 2026 coverage pathway for most Canadian psychedelic-assisted therapy patients is NOT through provincial drug plans. Instead:

1. Federal public servants → PSHCP / Canada Life Form M7520 for Spravato — see PSHCP Spravato Coverage
2. Private extended-health beneficiaries → private prior auth (Manulife, Sun Life, Green Shield, Blue Cross provincial branches) for Spravato — see Private Insurance Prior Authorization for Spravato
3. Albertans with Alberta Blue Cross plans → Alberta Blue Cross PAT coverage for ketamine-assisted therapy — see Alberta Blue Cross PAT Coverage
4. Ultra-resistant TRD Albertans → AHCIP Edmonton Misericordia/Grey Nuns public IV ketamine program — see Edmonton Misericordia/Grey Nuns
5. SAP-approved Quebec patients with end-of-life distress → RAMQ Farzin/Stephan precedent for psilocybin — see Quebec RAMQ Coverage
6. Veterans → VAC mental-health benefits — see VAC Coverage for Psychedelic-Assisted Therapy
7. Injured workers → Workers' compensation (WSIB Ontario, WCB Alberta, others) — see Workers' Compensation for Psychedelic-Assisted Therapy
8. Out-of-pocket for patients without applicable coverage

Frequently asked questions

Does any provincial drug plan cover Spravato? Generally no. Most provinces aligned with the December 2020 CDA-AMC Do Not Reimburse recommendation. Spravato is essentially private prior-auth or out-of-pocket through provincial public drug plans.

Does Quebec RAMQ cover psychedelic-assisted therapy? Yes for psilocybin via the December 2022 Farzin/Stephan precedent for SAP-approved Quebec patients with end-of-life distress. Not for ketamine, Spravato, or MDMA. See Quebec RAMQ Coverage.

What about Ontario's Exceptional Access Program? Spravato is theoretically eligible for ODB EAP via SADIE portal, but approval is rare given CDA-AMC Do Not Reimburse. Not the realistic pathway.

What about BC PharmaCare Special Authority? Same pattern — Spravato is theoretically eligible but rarely approved for off-formulary psychedelic-assisted therapy.

Does AHCIP Alberta cover ketamine? Through the Edmonton Misericordia/Grey Nuns publicly funded IV ketamine program for ultra-resistant TRD with psychiatric referral. This is the only Canadian publicly funded outpatient psychiatric ketamine pathway. See Edmonton Misericordia/Grey Nuns.

Why is Spravato not covered when ketamine has been used for decades? Spravato is the form with Health Canada approval (May 2020 for TRD). Generic ketamine for psychiatric use is off-label with no approved indication, so it doesn't fit standard formulary inclusion criteria. Spravato's non-coverage reflects CDA-AMC Do Not Reimburse — different reasons.

Will provinces ever cover psychedelic-assisted therapy more broadly? Possibly. Future expansion would require new CDA-AMC recommendations following Phase 3 trial updates, Health Canada NOC approvals (Compass psilocybin, Lykos MDMA-AT pending), and clinical-economic evidence supporting cost-effectiveness. Timeline uncertain.

What about Quebec residents — RAMQ for ketamine or MDMA? Not currently. RAMQ's December 2022 precedent was psilocybin-specific. Quebec patients pursuing ketamine, Spravato, or MDMA-AT face standard private-pay or alternative coverage frameworks.

What about psilocybin SAP for non-Quebec patients? SAP authorization is federal Health Canada framework available to all provinces. Quebec RAMQ is the only provincial public-funding precedent. Other Canadian provinces' SAP-pathway psilocybin patients face standard out-of-pocket payment unless covered through alternative pathways.

What's the realistic Canadian coverage pathway then? For most patients: private prior-auth Spravato (federal public servants via PSHCP, others via Manulife/Sun Life/Green Shield/Blue Cross), Alberta Blue Cross PAT for Albertans with eligible plans, VAC for veterans, workers' compensation for injured workers, and the AHCIP Edmonton public ketamine program for ultra-resistant TRD Albertans. Out-of-pocket for those without applicable coverage.

Sources

1. CDA-AMC (formerly CADTH) — Spravato CDEC Final Recommendation (December 2020): https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0621%20Spravato%20-%20CDEC%20Final%20Recommendation%20December%2018,%202020_for%20posting.pdf
2. INESSS — Spravato Quebec recommendation (November 2020): https://www.inesss.qc.ca/en/themes/medicaments/drug-products-undergoing-evaluation-and-evaluated/extract-notice-to-the-minister/spravato-5429.html
3. Health Canada DPD — Spravato: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98903
4. Ontario Exceptional Access Program: https://www.ontario.ca/page/exceptional-access-program
5. BC PharmaCare Special Authority: https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/pharmacare/programs/special-authority
6. Saskatchewan Exception Drug Status: https://www.saskatchewan.ca/residents/health/prescription-drug-plans-and-health-coverage/extended-benefits-and-drug-plan/exception-drug-status
7. RAMQ List of Medications: https://www.ramq.gouv.qc.ca/en/citizens/prescription-drug-insurance/find-out-whether-a-drug-covered
8. TheraPsil — Quebec first province to cover psilocybin therapy: https://therapsil.ca/quebec-first-province-to-cover-costs-of-psilocybin-assisted-psychotherapy-done-by-two-physicians/
9. Covenant Health — Edmonton Misericordia/Grey Nuns IV ketamine program: https://covenanthealth.ca/news-and-events/news/ketamine-used-to-treat-depression-at-the-misericordia-and-grey-nuns-hospitals

Related articles

• Insurance Coverage for Psychedelic-Assisted Therapy in Canada
• PSHCP / Canada Life Spravato Coverage
• Private Insurance Prior Authorization for Spravato
• Alberta Blue Cross PAT Coverage
• Quebec RAMQ Coverage for Psychedelic Therapy
• VAC Coverage for Psychedelic-Assisted Therapy
• Workers' Compensation for Psychedelic-Assisted Therapy
• Edmonton Misericordia/Grey Nuns Public Ketamine Program
• Insurance Appeals When Coverage Is Denied

Last updated: 2026-05-06